

Haematologica
HAEMATOL/2018/214429
Version 4

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial

Rohtesh S. Mehta, Roland Bassett, Amanda Olson, Julianne Chen, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Gheath Al-Atrash, Qaiser Bashir, Stefan O. Ciurea, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Jeffrey J. Molldrem, Yago Nieto, Betul Oran, Katayoun Rezvani, Muzaffar H. Qazilbash, Samer A. Srour, Elizabeth J. Shpall, Borje S. Andersson, Richard E. Champlin, and Uday R. Popat

Disclosures: None

Contributions: U.P. conceptualized the study design, helped with interpretation of data, and ensured compliance with the regulatory requirements for the clinical trial; R.S.M. contributed to the interpretation of data and wrote the manuscript; R.B. contributed to the data analysis and figures and wrote the statistical section of the manuscript; J.C. provided clinical data; B.C.V. helped with correlatives; J.K. performed the pharmacokinetic analysis of busulfan; S.A., A.M.A., P.A., G.A., Q.B., S.O.C, C.M.H, J.S.I, R.J., P.K., I.K., D.M., J.J.M., Y.N., A.O., B.O., S.P., K.R., M.H.Q., N.S., and E.J.S., enrolled patients in the study and monitored clinical responses; and R.E.C. and B.S.A. enrolled patients in the study, monitored patients' clinical responses, and conceptualized the study design.